Avacta Annual General Meeting and Shareholder Event Detailed Agenda
Avacta Group PLC – Second Milestone in AffyXell Joint Venture
Avacta Achieves Second Milestone in AffyXell Joint Venture Triggering Increased Equity Stake
Avacta Group PLC – Posting of Annual Report and Notice of AGM
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that its Annual Report and Accounts for the year ended 31 December
Avacta Group PLC has announced that the first patient has been dosed in the US in the AVA6000 Phase 1 trial.
Avacta Group plc, a life sciences company that develops targeted oncology drugs and diagnostics, has dosed the first patient in the US as part of its phase 1 multi-center trial
Avacta Group PLC (AIM:AVCT) Preliminary Results for the year ended 31 December 2022
A period of continued significant progress
Avacta Group PLC (AIM:AVCT) AVA3996 data poster presented at AACR
Avacta Presents AVA3996 Pre-clinical Data at the American Association for Cancer Research Meeting
Avacta shares: brief update for Q2 2023
Avacta has expanded its footprint in the US. The listing could be next.
Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study
Memorial Sloan Kettering Cancer Center and Fred Hutch Cancer Center are now open for patient enrolment to pre|CISION™ lead programme, AVA6000
Avacta Group PLC (AIM:AVCT) First Patient Dosed in Fifth Cohort of AVA6000
First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study
Avacta Group PLC (AIM:AVCT) Avacta Therapeutics Division Science Day
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is today holding a Science Day, focused on its Therapeutics Division, for institutional
Avacta Group PLC (AIM:AVCT) Successful Completion of Fourth Dose Escalation
Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study